Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy adults ≥ 18 years of age: A randomized, multicenter, phase II / III clinical trial

• Автори: Shrikant Sharma (Автор), Veer Bahadur Singh (Автор), Sanjay Kumar (Автор), Vipul Prajapati (Автор), Jitendra Patel (Автор), Rajesh Vukkala (Автор), Sanjay Kumar Jangid (Автор), Jayesh Sanmukhani (Автор), Gaurav Gupta (Автор), Pradip Patel (Автор), Ravindra Mittal (Автор), Reinhard Glueck (Автор)
• Формат: Книга
• Опубліковано: Taylor & Francis Group, 2018-06-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

This phase II / III clinical trial was conducted to evaluate the immunogenicity and safety of the Tetravalent Influenza vaccine (Split virion) I.P. (TetIV) developed indigenously in the country for the first time by M/s Cadila Healthcare Limited, India containing two influenza A and two influenza B...